title: Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts.
authors.affiliation: jcortes@mdanderson.org.
authors.forename: Preetesh
authors.initials: P
authors.lastname: Jain
authors.forename: Carlos Guillermo
authors.initials: CG
authors.lastname: Romo
authors.forename: Hanna J
authors.initials: HJ
authors.lastname: Khoury
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.forename: Jorge
authors.initials: J
authors.lastname: Cortes
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011724:Pyridazines / Q000627:therapeutic use*; D014158:Transcription, Genetic / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D011724:Pyridazines; C545373:ponatinib; D016044:Fusion Proteins, bcr-abl
keywords: chronic myeloid leukemia; chronic phase; e1a2; ponatinib